Active Awards Portfolio Dashboard
It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.
Disease | Cell Type | Therapeutic or Technology | Institution | Stage | Project Objective | Details |
---|---|---|---|---|---|---|
Autoimmune Disorder, Lupus, Systemic Lupus Erythematosus (SLE) | iPS Cell | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | Fate Therapeutics | Clinical Trial, Phase 1 or Phase 1/2 | ||
Immune Disease | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | ImmPACT-Bio, Inc. | Clinical Trial, Phase 2 | ||
Brain Cancer, Cancer, Solid Tumors | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | UCSF | Clinical Trial, Phase 1 or Phase 1/2 | |||
Neurological Disorders, Parkinson's Disease | iPS Cell | Personalized cell therapy, Therapeutic Approach | Aspen Neuroscience | Clinical Trial, Phase 1 or Phase 1/2 | ||
Neurological Disorders | Adult or Tissue Stem Cell | Small molecule therapy, Therapeutic Approach | Alto Neuroscience | Clinical Trial, Phase 2 | ||
Developmental Disorders, Neurological Disorders, Spina Bifida | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | UC Davis | Clinical Trial, Phase 2 | ||
Brain Cancer, Cancer, Solid Tumors | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | Stanford | Clinical Trial, Phase 1 or Phase 1/2 | ||
Blood Cancer, Cancer, Leukemia, Acute Myeloid (AML) | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | COH | Clinical Trial, Phase 1 or Phase 1/2 | |||
Neurological Disorders, Other | Biologic, Nucleic acid based therapy, Therapeutic Approach | UCSD | Clinical Trial, Phase 1 or Phase 1/2 | |||
Cancer, Melanoma, Solid Tumors | Somatic Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | Stanford | Clinical Trial, Phase 1 or Phase 1/2 | ||
Age-related macular degeneration, Vision Loss | Embryonic Stem Cell | Donor cell therapy, Therapeutic Approach | Regenerative Patch Technologies LLC | Clinical Trial, Phase 2 | ||
HIV/AIDS, Infectious Disease | Other | COH | Clinical Trial, Phase 1 or Phase 1/2 | |||
Corneal Damage, Vision Loss | Adult or Tissue Stem Cell | Biologic, Exosomes based therapy, Therapeutic Approach | Combangio | Clinical Trial, Phase 2 | ||
Bone or Cartilage Disease, Hearing Loss, Intellectual Disability, Metabolic Disorders, Neurological Disorders, Vision Loss | Somatic Cell | Personalized cell therapy, Therapeutic Approach | Immusoft Corporation | Clinical Trial, Phase 1 or Phase 1/2 | ||
Cancer, Solid Tumors | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | Eureka Therapeutics, Inc. | Clinical Trial, Phase 1 or Phase 1/2 | |||
Anemia, Blood Disorders | Adult or Tissue Stem Cell | Antibody, Biologic, Therapeutic Approach | Stanford | Clinical Trial, Phase 1 or Phase 1/2 | ||
B cell cancers, Blood Cancer, Cancer | Somatic Cell | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | Angiocrine | Clinical Trial, Phase 3 | ||
Bone or Cartilage Disease, Osteoarthritis | Somatic Cell | Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach | Genascence Corporation | Clinical Trial, Phase 1 or Phase 1/2 | ||
Cancer, Colon Cancer, Solid Tumors | Tachyon Therapeutics, Inc | Clinical Trial, Phase 1 or Phase 1/2 | ||||
Anemia, Blood Disorders | Somatic Cell | Cell processing & handling, Immune tolerance/management, Technology | COH | Clinical Trial, Phase 1 or Phase 1/2 | ||
Anemia, Blood Disorders, Bone Marrow Transplant and Viral Infection | Adult or Tissue Stem Cell | Immune tolerance/management, Technology | Stanford | Clinical Trial, Phase 1 or Phase 1/2 | ||
Epilepsy, Neurological Disorders | Embryonic Stem Cell | Donor cell therapy, Therapeutic Approach | Neurona Therapeutics | Clinical Trial, Phase 1 or Phase 1/2 | ||
HIV/AIDS, Infectious Disease | Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach | Excision BioTherapeutics | Clinical Trial, Phase 1 or Phase 1/2 | |||
Bladder or Urinary Tract Disorder, Skeletal/Smooth Muscle disorders | Somatic Cell | Technology, Tissue engineering | Wake Forest University Health Sciences | Clinical Trial, Phase 1 or Phase 1/2 | ||
Blood Disorders, IPEX Syndrome | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | Stanford | Clinical Trial, Phase 1 or Phase 1/2 | ||
Brain Cancer, Cancer, Solid Tumors | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | COH | Clinical Trial, Phase 1 or Phase 1/2 | ||
Muscle Injury, Skeletal/Smooth Muscle disorders | Adult or Tissue Stem Cell | Personalized cell therapy, Therapeutic Approach | UC Davis | Clinical Trial, Phase 1 or Phase 1/2 | ||
Cancer, Solid Tumors | Adult or Tissue Stem Cell | Personalized cell therapy, Therapeutic Approach | BioEclipse Therapeutics INC. | Clinical Trial, Phase 1 or Phase 1/2 | ||
Heart Disease, Heart failure | Embryonic Stem Cell | Donor cell therapy, Therapeutic Approach | Stanford | Clinical Trial, Phase 1 or Phase 1/2 | ||
Brain Cancer, Cancer, Solid Tumors | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | Stanford | Clinical Trial, Phase 1 or Phase 1/2 | ||
B cell cancers, Blood Cancer, Cancer, Leukemia, Leukemia, Acute Myeloid (AML) | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | Stanford | Clinical Trial, Phase 1 or Phase 1/2 | ||
Neurological Disorders, Stroke | Embryonic Stem Cell | Donor cell therapy, Therapeutic Approach | Stanford | Clinical Trial, Phase 1 or Phase 1/2 | ||
Amyotrophic Lateral Sclerosis, Neurological Disorders | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | Cedars-Sinai | Clinical Trial, Phase 1 or Phase 1/2 | ||
Brain Cancer, Cancer, Solid Tumors | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | COH | Clinical Trial, Phase 1 or Phase 1/2 | ||
HIV/AIDS, Immune Disease, Infectious Disease | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | UCSF | Clinical Trial, Phase 1 or Phase 1/2 | ||
Neurological Disorders, Parkinson's Disease | Vital Research Opportunity | Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach | Brain Neurotherapy Bio | Clinical Trial, Phase 1 or Phase 1/2 | ||
Corneal Damage, Vision Loss | Adult or Tissue Stem Cell | Personalized cell therapy, Therapeutic Approach | UCLA | Clinical Trial, Phase 1 or Phase 1/2 | ||
Retinitis Pigmentosa, Vision Loss | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | Cedars-Sinai | Clinical Trial, Phase 1 or Phase 1/2 | ||
Brain Cancer, Breast Cancer, Cancer, Solid Tumors | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | COH | Clinical Trial, Phase 1 or Phase 1/2 | ||
Cystinosis, Kidney Disease, Kidney Failure, Metabolic Disorders | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | UCSD | Clinical Trial, Phase 1 or Phase 1/2 | ||
Retinitis Pigmentosa, Vision Loss | Therapeutic Approach | jCyte | Clinical Trial, Phase 2 | |||
Diabetes, Metabolic Disorders, Type 1 diabetes | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | UCSF | Clinical Trial, Phase 1 or Phase 1/2 | ||
Blood Disorders, Severe Combined Immunodeficiency, X-linked (X-SCID) | Adult or Tissue Stem Cell | Antibody, Biologic, Therapeutic Approach | Jasper Therapeutics, Inc. | Clinical Trial, Phase 1 or Phase 1/2 | ||
Kidney Disease, Kidney Failure | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | Stanford | Clinical Trial, Phase 1 or Phase 1/2 | ||
Blood Disorders, Sickle Cell Disease | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | COH | Clinical Trial, Phase 1 or Phase 1/2 | ||
Blood Disorders, Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | UCSF | Clinical Trial, Phase 1 or Phase 1/2 | ||
Cancer, Lung Cancer, Solid Tumors | Adult or Tissue Stem Cell | Antibody, Biologic, Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | UCLA | Clinical Trial, Phase 1 or Phase 1/2 | ||
Kidney Disease, Kidney Failure | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | Medeor Therapeutics | Clinical Trial, Phase 3 | ||
Blood Cancer, Blood Disorders, Bone Marrow Transplant and Viral Infection, Cancer | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | CHLA | Clinical Trial, Phase 1 or Phase 1/2 | ||
Retinitis Pigmentosa, Vision Loss | Other | Donor cell therapy, Therapeutic Approach | jCyte | Clinical Trial, Phase 2 |